Formulary guidance and transparency from P&T to point of care


Reality Check on Migraine

Market access for migraine treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, almost 47% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: New oral medications for acute migraine — Eli Lilly and Co.’s Reyvow (lasmiditan), Allergan’s ubrogepant and Biohaven Pharmaceuticals’ CGRP antagonist rimegepant — likely won’t shake up formulary coverage for a condition that’s largely treated by generic triptan medications, pharmacy benefit experts say 
  • Key Findings: Most policies require diagnosis and use of triptan (generic) before ergotamines, and require use of generic ergotamine products prior to brand names. Policies for botulinum toxin usually require a step through preventative therapy

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.